Veranstaltungskalender
Markus Möhler(Heidelberg University), Druck Ausrüstung Kraft Premium GmbH, Rebecca A. Moss(Bristol-Myers Squibb (United States)), Joanna Blocka, Lena Seifert(Heidelberg University), Timothy J. Kennedy(Memorial Sloan Kettering Cancer Center), Paul H. Sugarbaker(American Institute for Cancer Research), Michael Ståhl(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Salma K. Jabbour(Rutgers, The State University of New Jersey), Niels Reinmuth(Asklepios Fachkliniken München-Gauting), Philipp Harter(Kliniken Essen-Mitte), Beate Rau(Medizinische Hochschule Hannover), Tanja Fehm(Düsseldorf University Hospital), Florian Reinhardt, Kay M. Westenfelder, Andreas Stephan Lübbe, Hans-Rudolf Raab, Claudia Witt, Andreas Brandl, Wieland Raue(Charité - Universitätsmedizin Berlin), Andreas Pascher(Charité - Universitätsmedizin Berlin), Gerald Kolb(Philipps University of Marburg), Christina Hadzitherodorou
Cited by 0
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|1.9k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879